SCHEMBL1413597

SCHEMBL1413597

CCS(=O)(=O)c1ccc(C(=O)NC(=O)c2ccc3c(c2)C(=O)N(C2CCC(=O)NC2=O)C3)cc1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 20/20 0.60
▸ CSNK1A1 P48729 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1413576 0.91 CRBN (0.62) CRBNCSNK1A1
SCHEMBL1413530 0.90 CRBN (0.53) CRBNCSNK1A1
SCHEMBL1413504 0.88 CRBN (0.59) CRBNCSNK1A1
SCHEMBL1413692 0.87 CRBN (0.62) CRBNCSNK1A1
SCHEMBL1413640 0.86 CRBN (0.57) CRBNCSNK1A1
SCHEMBL1413409 0.86 CRBN (0.63) CRBNCSNK1A1
SCHEMBL1413525 0.86 CRBN (0.57) CRBNCSNK1A1
SCHEMBL1413615 0.85 CRBN (0.60) CRBNCSNK1A1
SCHEMBL1413446 0.85 CRBN (0.62) CRBNCSNK1A1
SCHEMBL1413715 0.85 CRBN (0.62) CRBNCSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327013-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2019-04-24 — — EP disclosed
EP-3327013-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2018-05-30 — — EP disclosed
EP-3061758-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2018-01-31 — — EP disclosed
US-9801868-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2017-10-31 — — US disclosed
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2016-12-01 — — US disclosed
US-9447070-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2016-09-20 — — US disclosed
EP-3061758-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2016-08-31 — — EP disclosed
EP-2749559-B1 5-substituted isoindoline compounds CELGENE CORP (US) 2016-04-27 — — EP disclosed
EP-2291365-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2015-03-11 — — EP disclosed
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2015-01-01 — — US disclosed
US-8877780-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-11-04 — — US disclosed
EP-2749559-A1 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-07-02 — — EP disclosed
EP-2291365-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2011-03-09 — — EP disclosed
WO-2009145899-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-12-03 — — WO disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 CRBN 4610/4885CSNK1A1 554/4885
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 CRBN 4610/4885CSNK1A1 554/4885
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 CRBN 4610/4885CSNK1A1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback